Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study

  1. Alten, R.
  2. Gomez-Reino, J.
  3. Durez, P.
  4. Beaulieu, A.
  5. Sebba, A.
  6. Krammer, G.
  7. Preiss, R.
  8. Arulmani, U.
  9. Widmer, A.
  10. Gitton, X.
  11. Kellner, H.
Revista:
BMC Musculoskeletal Disorders

ISSN: 1471-2474

Ano de publicación: 2011

Volume: 12

Tipo: Artigo

DOI: 10.1186/1471-2474-12-153 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus